(RTTNews) - WuXi XDC, a global leading Contract Research, Development and Manufacturing Organization dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated ...
As more ADCs receive Accelerated Approval and Fast Track Designation, expediting the transition to the clinic becomes a strategic priority for developers. This underscores the growing need of having a ...
Mycenax Biotech Inc., a leading biologics CDMO based in Taiwan, announced strategic alliance with Spera Pharma Inc., a Japan-based expert in pharmaceutical chemistry, manufacturing, and controls (CMC) ...
SUZHOU, China, Nov. 13, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous ...
SAN DIEGO – December 10 th, 2015 — Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its ...
SUZHOU, China, Dec. 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co ...
Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bis ...
SUZHOU, China, Nov. 11, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous ...
TAIPEI, Sept. 15, 2025 /PRNewswire/ -- Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, today announced strategic alliance with SPERA PHARMA Inc., a Japan-based expert in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback